By Fineline Cube 
Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration (NMPA) has granted a second indication approval for Akeega (niraparib and abiraterone acetate) in combination with prednisone or prednisolone for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) harboring germline and/or somatic BRCA2 gene mutations.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Agency | NMPA (China) |
| Product | Akeega (niraparib + abiraterone acetate) + prednisone/prednisolone |
| Indication | mHSPC with BRCA2 mutations (germline/somatic) |
| Approval Basis | AMPLITUDE Phase III clinical trial |
| Previous Approval | October 2024 for mCRPC with BRCA mutations |
| Therapy Regimen | Akeega + prednisone + androgen deprivation therapy (ADT) |
Clinical Evidence – AMPLITUDE Phase III Trial
| Endpoint | Result (Akeega + ADT) | Comparator (Standard of Care + ADT) | Benefit |
|---|---|---|---|
| Radiographic Progression-Free Survival (rPFS) | Median not reached vs. 15.3 months | Standard of care + ADT | 54% risk reduction (HR=0.46; 95% CI: 0.32–0.66) |
| Time to Symptomatic Progression (TSP) | Significantly delayed | Standard of care + ADT | 59% risk reduction (HR=0.41; 95% CI: 0.29–0.65) |
| Safety Profile | Consistent with mCRPC experience | – | No new safety signals identified |
The AMPLITUDE trial demonstrated unprecedented efficacy in the biomarker-selected mHSPC population, establishing Akeega as a potential new standard of care for patients with BRCA2-mutated disease.
Strategic Market Impact
- Precision Oncology Expansion: This approval reinforces J&J’s commitment to precision medicine in prostate cancer, targeting the ~15% of mHSPC patients who harbor BRCA2 mutations.
- Commercial Synergy: Building on the October 2024 mCRPC approval, J&J now covers both major metastatic prostate cancer settings (hormone-sensitive and castration-resistant) for BRCA-mutated patients in China.
- Competitive Landscape: Akeega becomes the first dual-action therapy combining PARP inhibition (niraparib) with androgen receptor pathway inhibition (abiraterone) approved specifically for BRCA2-mutated mHSPC in China.
- Revenue Potential: With an estimated 45,000 new mHSPC cases annually in China and 12-15% BRCA2 mutation prevalence, peak annual sales could exceed $300 million in this indication alone.
Biomarker-Driven Treatment Paradigm
The approval underscores the growing importance of genomic testing in prostate cancer management. J&J is collaborating with Chinese diagnostic partners to expand access to BRCA testing, ensuring appropriate patient identification and treatment optimization.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Akeega. Actual results may differ due to risks including market adoption, competitive dynamics, and healthcare policy changes.-Fineline Info & Tech